Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite presented as an oral tablet for systemic use. It is employed to modify disease processes in autoimmune disorders and certain malignancies, acting as a disease-modifying antirheumatic drug (DMARD) in adults.

GNH USA supplies Methofill as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross-border procurement.

Methotrexate is used across several disease families, primarily autoimmune and oncologic conditions.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: diminishes skin plaque formation and severity. - Certain cancers (e.g., leukemia, lymphoma): interferes with rapid cell proliferation. - Crohn's disease: helps achieve remission by modulating immune response.

Methotrexate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral ulcers or mucositis. - Elevated liver enzymes.

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia. - Severe hepatic toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening infections due to immunosuppression.

When prescribing Methofill, several safety considerations should be observed.

- Pregnancy: contraindicated because of known teratogenic risk (Category X). - Renal function: assess baseline and monitor regularly to avoid accumulation. - Liver function: obtain baseline tests and conduct periodic monitoring. - Hematologic status: perform regular complete blood counts to detect marrow suppression. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Methofill interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Trimethoprim‑sulfamethoxazole: potentiates myelosuppression.

Moderate Interactions (Monitor Closely): - Penicillins: may reduce renal clearance of methotrexate. - Proton pump inhibitors: can affect gastrointestinal absorption. - Live vaccines: heightened infection risk due to immunosuppression.